Liftstream is an executive search recruitment company in the life sciences sector
5 trends for Drug Regulatory Affairs recruitment in 2014!
Authored by Karl Simpson
Posted in Job Hunting Advice, Orphan Drugs and Rare Diseases, Recruitment Market
Tagged biosimilars, BRICs, careers, careers in regulatory, disease specificity, emerging markets, Liftstream, Market Access, Orphan drugs, pricing reimbursement, rare diseases, recrutiment, regulatory affairs, regulatory recrutiment
Leave a comment
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Day 1 The World Orphan Drug Congress – Geneva
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Adaptive Licensing, clinical development, Clinical Trial Design, Corporate Development and Partnerships, EURORDIS, Geneva, HTA, IRDiRC, Market Access, Nyon, Orphan drugs, pricing and reimbursement, rare diseases, Shire HGT, Theresa Heggie, world orphan drug congress, world orphan drug congress 2012, Yann Le Cam
Leave a comment
NPS Pharmaceuticals gets ready to launch gastro orphan drug
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged commercial, endocrinology, europe, FDA, gastroenterology, Gattex, hormone, Market Access, marketing, Natpara, NPS Pharmaceuticals, Nycomed, Orphan Drug, patients, pricing and reimbursement, Revestive, short bowel syndrome, Takeda, teduglutide, ultra-rare diseases, USA
Leave a comment
The Market Access Challenge for Orphan Drugs
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ALS, Australia, BIA, EMA, EURODIS, FDA, Health Technology Assessment, HEOR, HTA's, Korea, Lou Gehrig’s Disease, Market Access, Motor Neurone Disease, NICE, Orphan Drug Act, Orphan drugs, Orphanet, Rare Disease, Rilutek, Shire, Singapore, Taiwan
Leave a comment